Should You Investigate BioTelemetry, Inc. (NASDAQ:BEAT) At US$39.65?

BioTelemetry, Inc. (NASDAQ:BEAT), which is in the healthcare business, and is based in United States, saw significant share price movement during recent months on the NASDAQGS, rising to highs of $51.65 and falling to the lows of $39.34. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether BioTelemetry's current trading price of $39.65 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at BioTelemetry’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for BioTelemetry

What's the opportunity in BioTelemetry?

BioTelemetry is currently overpriced based on my relative valuation model. In this instance, I’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. I find that BioTelemetry’s ratio of 28.64x is above its peer average of 19.55x, which suggests the stock is overvalued compared to the Healthcare industry. If you like the stock, you may want to keep an eye out for a potential price decline in the future. Since BioTelemetry’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What kind of growth will BioTelemetry generate?

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by a double-digit 15% in the upcoming year, the short-term outlook is positive for BioTelemetry. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? It seems like the market has well and truly priced in BEAT’s positive outlook, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe BEAT should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on BEAT for some time, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the optimistic prospect is encouraging for BEAT, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on BioTelemetry. You can find everything you need to know about BioTelemetry in the latest infographic research report. If you are no longer interested in BioTelemetry, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.